Hochschulschrift
Hemmbarkeit von humanen T-Zellen durch den FLT3-Kinase-Inhibitor Midostaurin im Vergleich zum SRC-Kinase-Inhibitor Dasatinib
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Deutsch
- Notes
-
Magdeburg, Universität, Dissertation, 2016
- Keyword
-
Zelle
Immunologie
Immunsystem
Lymphozyt
Leukozyt
Immunität
Resistenz
Immunchemie
- Event
-
Veröffentlichung
- (where)
-
Magdeburg
- (who)
-
Universitätsbibliothek
- (when)
-
2016
- Creator
-
Höding, Christine
- URN
-
urn:nbn:de:gbv:ma9:1-9133
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:46 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Object type
- Hochschulschrift
Associated
- Höding, Christine
- Universitätsbibliothek
Time of origin
- 2016
Other Objects (12)
Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines
Apoptoseinduktion in Lymphomzellen durch neue SRC-Kinase-Inhibitoren
CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML
Recent advances in pharmacological diversification of Src family kinase inhibitors
Therapeutic kinase inhibitors
Photoactivatable Kinase Inhibitors
Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL™), a multi-targeted kinase inhibitor
Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
Synergistic effect of FMS-like tyrosine kinase-3 (FLT3) inhibitors combined with a CDK7 inhibitor in FLT3-ITD-mutated acute myeloid leukemia
The Src family kinase inhibitor dasatinib delays pain-related behaviour and conserves bone in a rat model of cancer-induced bone pain
Photoswitchable Kinase Inhibitors to Reversibly Control Kinase Activity
Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines
Apoptoseinduktion in Lymphomzellen durch neue SRC-Kinase-Inhibitoren
CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML
Recent advances in pharmacological diversification of Src family kinase inhibitors
Therapeutic kinase inhibitors
Photoactivatable Kinase Inhibitors
Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL™), a multi-targeted kinase inhibitor
Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
Synergistic effect of FMS-like tyrosine kinase-3 (FLT3) inhibitors combined with a CDK7 inhibitor in FLT3-ITD-mutated acute myeloid leukemia
The Src family kinase inhibitor dasatinib delays pain-related behaviour and conserves bone in a rat model of cancer-induced bone pain
Photoswitchable Kinase Inhibitors to Reversibly Control Kinase Activity
Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines
Apoptoseinduktion in Lymphomzellen durch neue SRC-Kinase-Inhibitoren
CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML
Recent advances in pharmacological diversification of Src family kinase inhibitors
Therapeutic kinase inhibitors
Photoactivatable Kinase Inhibitors
Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL™), a multi-targeted kinase inhibitor
Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
Synergistic effect of FMS-like tyrosine kinase-3 (FLT3) inhibitors combined with a CDK7 inhibitor in FLT3-ITD-mutated acute myeloid leukemia
The Src family kinase inhibitor dasatinib delays pain-related behaviour and conserves bone in a rat model of cancer-induced bone pain